Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1996 1
1997 1
1998 2
1999 1
2000 3
2001 2
2002 3
2003 3
2004 1
2006 4
2007 2
2008 1
2009 2
2012 1
2013 2
2014 2
2015 1
2016 2
2017 2
2019 2
2020 5
2021 4
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. Hindricks G, et al. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Eur Heart J. 2021. PMID: 32860505 No abstract available.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.
Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A, Hissar S, Choo L, Musoke P, Mulenga V, Mave V, Joseph B, LeBeau K, Thomason MJ, Mboizi RB, Kapasa M, van der Zalm MM, Raichur P, Bhavani PK, McIlleron H, Demers AM, Aarnoutse R, Love-Koh J, Seddon JA, Welch SB, Graham SM, Hesseling AC, Gibb DM, Crook AM; SHINE Trial Team. Turkova A, et al. N Engl J Med. 2022 Mar 10;386(10):911-922. doi: 10.1056/NEJMoa2104535. N Engl J Med. 2022. PMID: 35263517 Free PMC article. Clinical Trial.
CONCLUSIONS: Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis. (Funded by the U.K. Medical Research Council and others; SHINE ISRCTN number, ISRCTN63579542.)....
CONCLUSIONS: Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere …
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Symmans WF, et al. JAMA Oncol. 2021 Nov 1;7(11):1654-1663. doi: 10.1001/jamaoncol.2021.3690. JAMA Oncol. 2021. PMID: 34529000 Free PMC article. Clinical Trial.
Entropy Landscaping of High-Entropy Carbides.
Hossain MD, Borman T, Oses C, Esters M, Toher C, Feng L, Kumar A, Fahrenholtz WG, Curtarolo S, Brenner D, LeBeau JM, Maria JP. Hossain MD, et al. Adv Mater. 2021 Oct;33(42):e2102904. doi: 10.1002/adma.202102904. Epub 2021 Sep 2. Adv Mater. 2021. PMID: 34476849
The calculations predict that in many compositions, the single-phase state becomes stable at extremely high temperatures (>3000 K). Consequently, rapid quenching rates are needed to preserve solubility at room temperature and facilitate physical characterization. ...
The calculations predict that in many compositions, the single-phase state becomes stable at extremely high temperatures (>3000 K) …
4-Phenylbutyrate protects against atherosclerotic lesion growth by increasing the expression of HSP25 in macrophages and in the circulation of Apoe-/- mice.
Lynn EG, Lhoták Š, Lebeau P, Byun JH, Chen J, Platko K, Shi C, O'Brien ER, Austin RC. Lynn EG, et al. FASEB J. 2019 Jul;33(7):8406-8422. doi: 10.1096/fj.201802293RR. Epub 2019 Apr 9. FASEB J. 2019. PMID: 30964709
Given that increased expression of HSP27 is inversely correlated with CVD risk, our findings suggest that 4-PBA protects against the early stages of atherogenesis in part by enhancing HSP27 levels, leading to inhibition of both macrophage cell death and monocyte-macrophage differ …
Given that increased expression of HSP27 is inversely correlated with CVD risk, our findings suggest that 4-PBA protects against the early s …
The Development of a Novel Nanobody Therapeutic for SARS-CoV-2.
Ye G, Gallant JP, Massey C, Shi K, Tai W, Zheng J, Odle AE, Vickers MA, Shang J, Wan Y, Drelich A, Kempaiah KR, Tat V, Perlman S, Du L, Tseng CT, Aihara H, LeBeau AM, Li F. Ye G, et al. bioRxiv [Preprint]. 2020 Nov 17:2020.11.17.386532. doi: 10.1101/2020.11.17.386532. bioRxiv. 2020. PMID: 33236012 Free PMC article. Updated. Preprint.
The lead drug possessing an Fc tag ( Nanosota-1C-Fc ) bound to SARS-CoV-2 RBD with a K (d) of 15.7picomolar (3000 times more tightly than ACE2 did) and inhibited SARS-CoV-2 infection with an ND (50) of 0.16microgram/milliliter (6000 times more potently than ACE2 did). ...
The lead drug possessing an Fc tag ( Nanosota-1C-Fc ) bound to SARS-CoV-2 RBD with a K (d) of 15.7picomolar (3000 times more tightly …
Revealing Site Occupancy in a Complex Oxide: Terbium Iron Garnet.
Rosenberg E, Bauer J, Cho E, Kumar A, Pelliciari J, Occhialini CA, Ning S, Kaczmarek A, Rosenberg R, Freeland JW, Chen YC, Wang JP, LeBeau J, Comin R, de Groot FMF, Ross CA. Rosenberg E, et al. Small. 2023 Jul;19(30):e2300824. doi: 10.1002/smll.202300824. Epub 2023 Apr 14. Small. 2023. PMID: 37060220
The magnetic properties of the TbIG are sensitive to site occupancy, exhibiting a higher compensation temperature (by 90 K) and a lower Curie temperature (by 40 K) than the bulk Tb(3) Fe(5) O(12) garnet. ...
The magnetic properties of the TbIG are sensitive to site occupancy, exhibiting a higher compensation temperature (by 90 K) and a low …
50 results